

Clinical guideline updates are available on anthem.com

Published: Jan 1, 2019 - **Policy Updates** / Medical Policy & Clinical Guidelines

The following new and revised medical policies were endorsed at the November 8, 2018 Medical Policy & Technology Assessment Committee (MPTAC) meeting. These, and all Anthem medical policies, are available at [anthem.com/providers](https://www.anthem.com/providers) > scroll down and select 'Find Resources for [state]' > [Medical Policies and Clinical UM Guidelines](#).

If you do not have access to the internet, you may request a hard copy of any updated policy by contacting the [Provider Call Center](#).

Revised clinical guideline effective November 15, 2018

(The following adopted guideline was revised to expand medical necessity indications or criteria

- CG-DRUG-88 - Dupilumab (Dupixent®)

Revised clinical guidelines effective December 12, 2018

(The following adopted guidelines were revised to expand medical necessity indications or criteria.)

- CG-DRUG-62 - Fulvestrant (FASLODEX®)
- CG-DRUG-63 - Levoleucovorin Products
- CG-DRUG-65 - Tumor Necrosis Factor Antagonists
- CG-DRUG-78 - Antihemophilic Factor and Clotting Factors
- CG-DRUG-107 - Pharmacotherapy for Hereditary Angioedema
- CG-GENE-03 - BRAF Mutation Analysis
- CG-SURG-60 - Cervical Total Disc Arthroplasty
- CG-THER-RAD-03 - Radioimmunotherapy and Somatostatin Receptor Targeted Radiotherapy

Revised clinical guidelines effective December 12, 2018

(The following adopted guidelines were reviewed and had no significant changes to the policy position or criteria.)

- CG-DRUG-38 - Pemetrexed (Alimta®)
- CG-DRUG-42 - Asparagine Specific Enzymes (Asparaginase)
- CG-DRUG-44 - Pegloticase (Krystexxa®)
- CG-DRUG-45 - Octreotide Acetate (Sandostatin, Sandostatin LAR)
- CG-DRUG-54 - Agalsidase beta (Fabrazyme®)
- CG-DRUG-64 - FDA-Approved Biosimilar Products
- CG-DRUG-66 - Panitumumab (Vectibix®)
- CG-DRUG-70 - Eribulin mesylate (Halaven®)
- CG-DRUG-71 - Ziv-aflibercept (Zaltrap®)
- CG-DRUG-75 - Romiplostim (Nplate®)
- CG-DRUG-76 - Plerixafor Injection (Mozobil™)
- CG-DRUG-79 - Siltuximab (Sylvant®)
- CG-DRUG-80 - Cabazitaxel (Jevtana)
- CG-DRUG-87 - Vedolizumab (Entyvio®)
- CG-MED-19 - Custodial Care
- CG-MED-26 - Neonatal Levels of Care
- CG-MED-67 - Melanoma Vaccines
- CG-MED-68 - Therapeutic Apheresis
- CG-REHAB-07 - Skilled Nursing and Skilled Rehabilitation Services
- CG-SURG-60 - Cervical Total Disc Arthroplasty
- CG-SURG-62 - Radiofrequency Ablation to Treat Tumors Outside the Liver
- CG-THER-RAD-04 - Selective Internal Radiation Therapy (SIRT) of Primary or Metastatic Liver Tumors

Revised clinical guideline effective December 12, 2018

(The following adopted guideline was updated with new procedure and/or diagnosis codes.)

- CG-DRUG-16 - White Blood Cell Growth Factors

Revised clinical guidelines effective December 27, 2018

(The following adopted guidelines were updated with new procedure and/or diagnosis codes.)

- CG-BEH-02 - Adaptive Behavioral Treatment for Autism Spectrum Disorder
- CG-DME-43 - Oscillatory Devices for Airway Clearance (High Frequency Chest Compression)
- CG-DRUG-29 - Hyaluronan Injections
- CG-DRUG-61 - Gonadotropin Releasing Hormone Analogs for the Treatment of Non-Oncologic Indications
- CG-DRUG-68 - Bevacizumab (Avastin®) for Non-Ophthalmologic Indications
- CG-DRUG-90 - Intravitreal Treatment for Retinal Vascular Conditions
- CG-DRUG-94 - Rituximab (Rituxan®) for Non-Oncologic Indications
- CG-MED-74 - Implantable Ambulatory Event Monitors and Mobile Cardiac Telemetry

Archived clinical guideline effective January 1, 2019

(The following adopted guideline has been archived and has been replaced by AIM guidelines.)

- CG-SURG-60 - Cervical Total Disc Arthroplasty

Revised clinical guidelines effective January 1, 2019

(The following adopted guidelines were revised and had no significant changes to the policy position or criteria.)

- CG-DME-40 - Noninvasive Electrical Bone Growth Stimulation of the Appendicular Skeleton
- CG-MED-65 - Manipulation Under Anesthesia

Adopted clinical guidelines effective January 3, 2019

(The following guidelines were previously medical policies and have been adopted and have no significant changes.)

- CG-MED-79 - Diaphragmatic/Phrenic Nerve Stimulation and Diaphragm Pacing Systems
- CG-MED-80 - Positron Emission Tomography (PET) and PET/CT Fusion

Revised clinical guidelines effective April 1, 2019

(The following adopted guidelines were revised and might result in services that were previously covered but may now be found to be not medically necessary.)

- CG-DRUG-77 - Radium Ra 223 Dichloride (Xofigo®)
- CG-GENE-01 - Janus Kinase 2 (JAK2) V617F and JAK2 exon 12 Gene Mutation Assays
- CG-SURG-27 - Sex Reassignment Surgery
- CG-SURG-61 - Cryosurgical Ablation of Solid Tumors Outside the Liver

URL: <https://providernews.anthem.com/maine/article/clinical-guideline-updates-are-available-on-anthemcom-10>

Featured In:

January 2019 Anthem Maine Provider Newsletter

Anthem Blue Cross and Blue Shield is the trade name of: In Colorado Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. In Connecticut: Anthem Health Plans, Inc. In Georgia: Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. In Indiana: Anthem Insurance Companies, Inc. In Kentucky: Anthem Health Plans of Kentucky, Inc. In Maine: Anthem Health Plans of Maine, Inc. In Missouri (excluding 30 counties in the Kansas City area): RightCHOICE® Managed Care, Inc. (RIT), Healthy Alliance® Life Insurance Company (HALIC), and HMO Missouri, Inc. RIT and certain affiliates administer non-HMO benefits underwritten by HALIC and HMO benefits underwritten by HMO Missouri, Inc. RIT and certain affiliates only provide administrative services for self-funded plans and do not underwrite benefits. In Nevada: Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. dba HMO Nevada. In New Hampshire: Anthem Health Plans of New Hampshire, Inc. HMO plans are administered by Anthem Health Plans of New Hampshire, Inc. and underwritten by Matthew Thornton Health Plan, Inc. In Ohio: Community Insurance Company. In Virginia: Anthem Health Plans of Virginia, Inc. trades as Anthem Blue Cross and Blue Shield in Virginia, and its service area is all of Virginia except for the City of Fairfax, the Town of Vienna, and the area east of State Route 123. In Wisconsin: Blue Cross Blue Shield of Wisconsin (BCBSWI), which underwrites or administers the PPO and indemnity policies and underwrites the out of network benefits in POS policies offered by CompCare or WCIC; CompCare Health Services Insurance Corporation (CompCare) underwrites or administers the HMO policies and Wisconsin Collaborative Insurance Company (WCIC) underwrites or administers Well Priority HMO or POS policies. Independent licensees of the Blue Cross and Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. Use of the Anthem websites constitutes your agreement with our Terms of Use.
